Antipsychotic adherence falls when patient financial incentives are withdrawn
Offering payments to patients to receive injectable antipsychotics is only effective while the incentives are provided, study finds.
Results from a randomised controlled trial published in 2009 showed that offering financial incentives to patients with psychotic disorders improved adherence to long-acting injectable antipsychotics over a year, but it is unknown whether adherence continues after incentives are withdrawn.
To explore, researchers followed up patients from the original study at 6 months and 24 months after the intervention ended. The original study involved 141 patients and those randomised to the intervention received £15 per injection.
The team found there was no significant difference in adherence rates between the intervention and control groups at either time point (71% vs 77% at 6 months; 68% vs 74% at 24 months).
Reporting in BMJ Open (online, 21 September 2016), the researchers say the results are in line with previous literature showing that incentives only improve health-related behaviours for the duration they are provided.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201807
Recommended from Pharmaceutical Press